June - 2013 - American Association for Clinical Chemistry

DACC NEWS
Volume 29, Number 2, June 2013
ANIMAL CLINICAL CHEMISTRY
2013 Annual Meeting Edition
Message from the Chair
In This Issue:
Pg.3 DACC Fall Webinar
Pg.5 Annual Meeting Schedule
While sitting here authoring my second Message
from the Chair for the 2013 DACC Summer Newsletter, I am truly amazed how quickly time has
passed by. Just a short while ago, I was writing
this for the DACC Spring newsletter as well as finalizing last minute details
for the Spring Symposium
that was held at Novartis
in East Hanover NJ.
On the topic of this
year‟s Spring Meeting, on
behalf of the DACC membership, we extend a
hearty thank you to Liane
Yanas and her colleagues
at Novartis for sponsoring
the meeting and providing
a delicious lunch as well
as a very nice auditorium.
I also want to thank Tom Brown and Michael
Green from IDEXX as well as Elizabeth Wiet from
Sysmex for co-sponsoring the educational event
through the DACC “Meet the Speakers” mixer and
awards reception. This was a fun event, with
great food and I truly enjoyed getting to meet
so many wonderful people. I would also like
to thank Bob Emmons for presenting Edie
Williams, Rosemary Nicklaus, and Patricia
Carthage the DACC/AACC Certificate of Rec-
Pg.6 Lunch & Learn Program
Pg.7 Translational Medicine Symposium
Pg.8 Annual Meeting Poster Titles
Pg.9 Award for Outstanding Contributions
Pg.11 Remembrance of Kent Gossett
Pg.12 Photos from Spring Symposium
ognition for Meritorious Service, Dedication, and
Contributions to the AACC Division of Animal
Clinical Chemistry for enhancing and advancing
the practice and profession of animal clinical laboratory medicine. It has been the good fortune of
the division that these three individuals decided to
dedicate their scientific careers as DACC members.
Hopefully you were able to attend this year‟s
DACC Spring Meeting on April 19th entitled
“Cardiac and Skeletal Muscle Injury In Drug Development: Advances in Biomarkers, Assessment
and Clinical Translation”. As mentioned, this symposium was hosted and sponsored by the Drug
Safety Department of Novartis Pharmaceutical Research & Development and was very
well attended. This scientific educational
event included eight expert speakers and was
divided in two sessions.
The morning
1
<Message from the Chair continued . . .>
session focused primarily on skeletal muscle injury, while the afternoon session addressed cardiac injury. Rick Goldstein from Pfizer kicked off
the meeting by providing an overview, application
and utility of a muscle injury panel to monitor and
differentiate cardiac and skeletal muscle injury in
multi-species as well as touching on the cross reactivity of rodent-specific assays in both canine
and non human primate. This was a very nice introduction for the next speaker who was Dr. Warren Glaab from Merck Research Laboratories, the
co-chair of the PSTC Skeletal Muscle Working
Group. Building on Dr. Goldstein‟s presentation,
Dr. Glaab gave a very nice talk which focused on
the Skeletal Muscle Working Group‟s identification
of novel skeletal muscle biomarker candidates,
validation work, as well as outlining the group‟s
translational strategy for use in the clinic. Dr.
Glaab concluded with the identification of normal
and disease populations needed to establish
baseline measurements of these novel biomarkers
and the next steps to secure clinical samples from
drug-induced skeletal muscle toxicities. The next
two speakers were subject matter experts in the
field of metabolomics. Dr. Brante Sampey from
Metabolon focused on the identification and clinical translation of early biomarkers using metabolic
approaches. This presentation conveyed that a
profound understanding of the underlying biology
is needed to drive predictive clinical success and
safety. Dr. Sampey gave a very extensive overview of how metabolomic studies demonstrate the
merits for the predictive translation from discovery
to clinical application as it relates to therapeutic
targets and biomarkers of cardiac and skeletal disease. With the continued theme of metabolomics
related to skeletal muscle injury, Dr. Nelly Aranibar from Bristol-Myers Squibb presented 1- and 3methylhistidine as biomarkers of drug related
myotoxicity. Dr. Aranibar summarized data compiled from a study following toxic doses of cerivastatin in Spague-Dawley rats. Dr. Carl Morris from
Pfizer concluded the morning skeletal muscle session discussing his learnings from the development of myostatin inhibitors. Dr. Morris shared an
extensive data set highlighting findings from
mouse and NHP safety and efficacy studies using
ActRIIB-Fc or MYO-029. The data showed optimism with myostatin inhibitor development for the
treatment of muscle dysfunction.
The afternoon session included three speakers
who focused on contractility and cardiac biomarkers to assess cardiac injury. Dr. Gregory
Friedrichs from Novartis began the afternoon session with cardiac contractility as an important parameter of cardiovascular function. He emphasized that a thorough evaluation of cardiac contractility is necessary for an integrated preclinical
cardiovascular assessment to provide safer molecules for clinical development and submission.
Dr. William Reagan followed with the use of cardiac Troponin as a preclinical biomarker for assessing cardiac myodegeneration and necrosis.
Dr. Reagan discussed the document entitled
“Qualification of Troponin as a Biomarker of Cardiac Toxicity” as well as the qualification process
with the FDA including context of use of this biomarker. He also focused his presentation on the
effective use of cardiac Troponin in the non human primate. Dr. Michael Dunn from HoffmanLaRoche and co-chair of the PSTC cardiac Hypertrophy Working Group concluded the afternoon
cardiac session with an overview of the application and translatability of N-Terminal Proatrial Natriuretic Peptide in non clinical drug safety evaluation. He gave a very nice summary of serum NTproANP as a physiologically relevant biomarker
and demonstrated that it has a translatable application and potential to improve risk assessments
for cardiovascular toxicity in patients.
The goal of this skeletal and cardiac muscle
symposium was to learn about issues related to
skeletal and cardiac injury, to be aware of preclinical predictive assays and models currently in use
or being evaluated to reduce clinical skeletal and
cardiac injury in late-stage clinical trials, to understand the use of routine and exploratory skeletal
and cardiac biomarkers, to be informed on current
consortium activities that are developing, and assessing new skeletal and cardiac biomarkers to
eventually ensure patient safety.
The DACC wishes to extend a huge THANK
YOU to all of the speakers who took the time out
of their extremely busy schedules to present at
this symposium.
Summer is here and that means… Please register
for the Annual AACC Meeting if you have not
done so already!! This meeting will be the next
opportunity where the DACC family will have the
opportunity to get together. The Annual Meeting
in Houston Texas is July 27th through August 1st
2013. Please make your travel and registration
arrangements now.
Here is a list of DACC activities that are scheduled throughout the week of the AACC Annual
meeting. I hope you will be able to attend all of
the scheduled events. The DACC Executive
2
<Message from the Chair continued . . .>
Committee will have its Business Meeting on Monday July 29th from 9:00-11:00 am at the Hilton
Americas Hotel. This is a meeting open to all
DACC members and we encourage all to attend.
This meeting gives members the opportunity to
hear what is going on in the division as well as the
opportunity to get more involved by volunteering
for a committee position or the planning of future
DACC events. Dave Desmond, our 2013 Chair–
Elect has put together the DACC Lunch and Learn
session that will take place on Monday July 29th
from noon until 3:00pm at the Hilton Americas Hotel.
The Lunch and Learn session, titled
“Emerging Technologies in Clinical Pathology”, will include multiple scientific presentations
as well as a presentation by the 2013 DACC Outstanding Contributions to Animal Clinical Chemistry award recipient, Dr. Joseph Dooley. The
Lunch and Learn is a great interactive experience
as well as a networking opportunity with a delicious lunch included. On Tuesday evening July
30th, Siemens will be continuing its dedication to
the animal division by hosting the 2013 DACC
Outstanding Contributions to Animal Clinical
Chemistry award ceremony. Please join us as we
present Dr. Joseph Dooley this year‟s award.
Congratulations Dr. Dooley. Our DACC PastChair Kay Criswell is principle organizer of the
DACC Translational Medicine Symposium entitled
“Lost in Translation? -Predicting and Insuring
 Rich
DACC Fall Webinar
Clinical Pathology Aspects of Stress
!!
Speaker: Nancy Everds, Amgen, Inc., Seattle WA
ee
Fr
ee
r
F
!!
Pharmacologic Efficacy and Safety from PreClinical”. This morning symposium will be held
on August 1st from 9:30am to 12:00pm. This session (AACC no. 35103) will focus on predicting
pharmaceutical safety and efficacy from preclinical data. Discussion will focus on suitability of
pre-clinical animal models, biomarkers of renal
toxicity, and unique challenges and opportunities
posed by individualizing therapy in cancer patients. Also, don‟t forget to visit the Animal Division Poster Session on Wednesday.
Another upcoming educational event sponsored
by the DACC this Fall will be a free webinar delivered via WebEx. This webinar speaker will be Dr.
Nancy Everds from Amgen, and she will be presenting “Clinical Pathology Aspects of Stress”.
Since our first webinar had over 50 attendees and
all of the feedback received was very positive, the
DACC Executive Committee considered this first
free webinar a success and the division is proud
to present another free webinar in the Fall. Stay
tuned to our listserv for more details.
As highlighted earlier, the success of the DACC is
dependent upon volunteers, as well as, a core
group of individuals that are willing to help new
members in these leadership roles. If you are interested in volunteering, please feel free to contact me anytime.
See you soon at the Annual AACC meeting in
Houston Texas.
Stay Tuned to the DACC Listserv for Details
Stress often occurs during toxicity studies. The perception of sensory stimuli as stressful primarily results
in catecholamine release and activation of the hypothalamic–pituitary–adrenal (HPA) axis to increase
serum glucocorticoid concentrations. Downstream effects of these neuroendocrine signals may include
effects on hematologic and clinical chemistry measurements as well as effects on other commonly measured parameters such as decreased total body weights or body weight gain; food consumption and activity; altered organ weights (e.g., thymus, spleen, adrenal); lymphocyte depletion in thymus and spleen;
and altered reproductive functions. Typically, only some of these findings occur in a given study. Determining whether effects are the result of stress requires a weight-of-evidence approach. Understanding
clinical pathology changes associated with the stress of procedures and toxicities is important for accurate attribution of data to test article.
3
Welcome
Diagnostica Stago
to DACC’s Family
of Supporters!
DACC Supporters
Sustaining Sponsors
Diagnostica Stago
IDEXX Laboratories
Novartis Pharmaceuticals
Siemens Healthcare Diagnostics
Sysmex America, Inc.
Diagnostica Stago
Recently Partnered
with the DACC as a
Sustaining Sponsor
of the Division!
Benefactors
GlaxoSmithKline
Hoffmann-LaRoche, Inc.
Merck & Co., Inc.
Merck Research Laboratories
Pfizer Global Research and Development
Our Newest Sponsor!
Through a Generous
Donation.
Patrons
Kay A. Criswell, PhD, DABT, –Pfizer, Inc.
Richard P. Giovanelli, –Pfizer, Inc.
Friends
Supporting Continuing
DACC Scientific and
Educational Programs.
Karissa Adkins, –Pfizer, Inc.
Leigh Anderson –Plasma Proteome Institute
Nelly Aranibar –Bristol-Myers Squibb
Steven R. Binder –Bio-Rad Laboratories
Michael Dunn –Hofmann-LaRoche Inc.
Mark Fidock –Huntingdon Life Sciences
Gregory Friedrichs –Novartis
Warren Glaab –Merck Research Laboratories
Richard Goldstein –Pfizer Inc.
John Jakubczak –Pfizer, Inc.
Jon Kimball –The Potter-Hawkins Group
Igor Mikaelian –Hoffmann-La Roche
Carl Morris –Pfizer, Inc.
Rounak Nassirpour –Pfizer, Inc.
Jonathan Phillips –Boehringer-Ingelheim
William J. Reagan –Pfizer, Inc.
Brante Sampey –Metabolon
Sharon Sokolowski –Pfizer, Inc.
4
2013 AACC/DACC Annual Meeting
Houston, TX
Sunday – July 28
Annual Meeting Opening Mixer
6:45pm – 8:00pm
Hilton Americas Hotel –Grand Ballroom
Open to All Registrants. Enjoy Networking with DACC Members!
Free Drinks!
Monday – July 29
DACC Executive Committee Meeting
9:00am – 11:00am
Hilton Americas Hotel –Meeting Room 339A&B
Open to All Members! Come Join in the Planning of DACC Activities!
DACC General Business Meeting and Lunch & Learn Session
Hilton Americas Hotel –Meeting Room 336A&B
Generously Supported by IDEXX Laboratories and Sysmex America
RSVP (Yeses Only) to Dave at [email protected] by July 15
12:00pm – 3:00pm
Free Lunch!
Tuesday – July 30
DACC Awards Presentation Reception and Mixer
Evening: TBD
Recognizing an Outstanding Contributor to Animal Clinical Chemistry
Generously Hosted by Siemens Healthcare Diagnostics
Watch the DACC Listserv for Details
Free Dinner!
Wednesday – July 31
Animal Clinical Chemistry Poster Session
(Session 12)
9:30am – 5:00pm
http://www.aacc.org/events/Annual_Meeting/abstracts/Documents/AACC_13_AM_B01-B09.pdf
Thursday – August 1
DACC Translational Medicine Symposium (Session 35103)
9:30am – 12:00pm
Lost in Translation? – Predicting and Insuring Pharmacologic
Efficacy and Safety from Pre-Clinical
Free Session!
Moderator: Kay Criswell, Pfizer, Inc. Groton, CT
Non-clinical Hematologic Toxicity and its Relevance to Human Safety
Nancy Everds, Amgen, Inc., Seattle, WA
Translational Renal Safety Biomarkers: A Consortium-Based Approach
Stephan Sultana, Novartis Pharmaceutical Company, Cambridge, MA
The Utility of Precision Medicine Approaches to Select Patients for
Clinical Trials in Oncology
James Christensen, Pfizer, Inc., San Diego, CA
Note: Register for this Symposium at:
www.aacc.org/events/annual_meeting/conferenceprogram
5
Division of Animal Clinical Chemistry
DACC Lunch & Learn
"Emerging Technologies in Clinical Pathology"
Monday – July 29th, 2013
Hilton Americas Hotel, Houston
The DACC Lunch & Learn session welcomes keynote speaker Joseph F. Dooley, PhD, DABCC,
FACB . Dr. Dooley is the recipient of the 2013 DACC Award for Outstanding Contributions to Animal Clinical Chemistry. The award recognizes the outstanding achievements of an individual who
has made significant contributions in the field of animal clinical chemistry in its broadest sense
including teaching, training, practicing and research.
Keynote Presentation: Title of Talk to Be Revealed at the Session
Joseph F. Dooley
Abstract not available.
Evaluation and Implementation of Hematology Automation in a Multispecies
Clinical Pathology Laboratory
Samantha Wildeboer, Pfizer, Inc., Groton, CT
Hematology sample processing often requires time consuming preparation and
handling of samples. In order to improve laboratory efficiency, we acquired two
automation platforms, an automated slide maker and stainer and cell imaging and
pre-classification software in our multispecies laboratory. This presentation will review the optimization, validation, assessment of process workflow and implementation of the Sysmex SP-1000iTM automated slide preparation unit and CellaVisionTM DM96 automated cell imaging instrumentation for use in our multispecies
laboratory.
Laboratory Information System Technology: Is Your Lab in the Driver’s Seat
or Locked in the Trunk?
Johann Wisniewski, Pfizer, Inc., Groton, CT
Advancements in technology and regulatory compliance coupled with staffing
shortages presents new challenges for the modern clinical laboratory in the quest
for efficiency. Implementing systems management approaches such as rules
based automation, customization of LIS applications, and system monitoring tools
are key to achieving maximal laboratory productivity.
6
DACC Annual Meeting Symposium
Thursday – August 1st, 2013
Advances in Translational Medicine: Understanding Translatability at the
Platform, Organ, and Therapeutic Area Levels
Translational and precision medicine have become extensively utilized terms in drug development. Translational medicine is a process of turning biological research discoveries in preclinical (nonhuman) models into
new drugs and biological devices to improve patient care. Whereas, precision medicine is an approach to discovering and developing medicines and vaccines that has the potential to deliver superior outcomes for patients by coupling clinical and genomic or molecular information to understand the biological basis of human
disease. Although better understanding of the translation of preclinical results and application of precision
medicine approaches are beginning to improve diagnostic and treatment options, it is not without significant
challenges and further hurdles.
This 3-speaker session will address the challenges of translatability at the platform, organ, and therapeutic
area levels. Some platforms, such as hematology, are believed to be highly translatable from preclinical species to human. The first presentation will explore whether animal models of hematologic toxicity are good predictors of human toxicity, and will also focus on hematologic disturbances associated with biotherapeutic administration and their relevance to human adverse events.
Even when new biomarkers achieve regulatory acceptance as predictive of organ toxicity in animals, confirming translation to humans remains elusive. In 2010, the PSTC (Predictive Safety Testing Consortium) published a number of newly qualified preclinical kidney safety biomarkers. The tests used to determine drug
safety have not changed in decades. These new markers have the potential to improve the predictivity of kidney toxicity. The second presentation will provide a view into the complexity and progress of the on-going
clinical trials to translate these new kidney markers in humans.
Finally, it has long been recognized that even though patients have the same disease, they do not respond
similarly to the same medication. The third lecture will focus on a precision medicine approach for drug development. Cancer is a disease of the genome, and each tumor has its own unique genetic changes. By understanding the molecular targets that underlie tumors it becomes possible to subgroup patients with similar genetic and physical characteristics to predict which patients will benefit most from certain drugs.
Non-clinical Hematologic Toxicity and its Relevance to Human Safety
Nancy Everds, Amgen, Inc., Seattle, WA
This presentation will explore whether animal models of hematologic toxicity are good predictors of human
toxicity, and will also focus on hematologic alterations associated with biotherapeutic administration and their
relevance to human safety. Even when new biomarkers achieve regulatory acceptance as predictive of organ
toxicity in animals, confirming translation to humans remains elusive.
Translational Renal Safety Biomarkers: A Consortium-Based Approach
Stephan Sultana, Novartis Pharmaceutical Company, Cambridge, MA
This presentation will provide a view into the complexity and progress of the on-going clinical trials to translate these new kidney markers in humans. In 2010, the PSTC published a number of newly qualified preclinical kidney safety biomarkers. These new markers have the potential to improve the predictivity of kidney toxicity beyond the tests that have been used for decades.
The Utility of Precision Medicine Approaches to Select Patients for Clinical Trials
in Oncology
James Christensen, Pfizer, Inc., San Diego, CA
This lecture will focus on a precision medicine approach for drug development. It has long been recognized
that even though patients have the same disease, they do not respond similarly to the same medication. Cancer is a disease of the genome, and each tumor has its own unique genetic changes. By understanding the
molecular targets that underlie tumors it becomes possible to subgroup patients with similar genetic and
physical characteristics to predict which patients will benefit most from certain drugs.
7
Animal Clinical Chemistry Poster Session
Wednesday – July 31, 2013, 9:30am – 5:00pm
Session 12: Link to Abstracts
B-01: Method Modification, Analytical Validation and Correlation of Alpha-2-Macroglobulin Assay for Use with Rat Serum on the Siemens Advia 1800 Automated Clinical
Chemistry Analyzer
D. Carraher, et al., Pfizer, Andover MA with Dako Denmark A/S, Glostrup, Denmark
B-02: Rat Lipid Comparison with Beckman DXC and AU Reagents
B. Robeson, et al., Marshfield Labs / Marshfield Clinic, Marshfield, WI
B-03: Validation of an Automated Cystatin C Assay in Canine Serum, Plasma and
Urine to Support Pre-Clinical Toxicology Studies
S. E. Wildeboer, R. P. Giovanelli, J. H. Bock, W. J. Reagan, Pfizer Global Research and
Development, Groton, CT
B-04: Optimization, Validation, and Implementation of Hematology Automation in a
Multispecies Clinical Pathology Laboratory
S. E. Wildeboer, A. G. Bull, J. E. Graves, C. Phanthalansy, R. P. Giovanelli, Pfizer Global
Research and Development, Groton, CT
B-05: Determination of Total Serum Cholesterol, HDL-C, and LDL-C in Sera from
Humans and Laboratory Animals Using 3 Reagent Systems and FPLC
N. Everds, M. Zhou, L. Ross, S. Z. Ratia, P. Fordstrom, J. F. Schroeder, A. D. Aulbach.
Amgen, Inc., Seattle, WA, South San Francisco, CA, and Thousand Oaks, CA, with MPI
Research, Mattawan, MI
B-06: Development of Immunoassays for Quantification of NT-proBNP in Canine Blood
K. R. Seferian, et al., HyTest LTD, Turku, Finland
B-07: The Effects of N-acetylcysteine and Ozone Therapy on Oxidative Stress and
Inflammation in Acetaminophen-induced Nephrotoxicity Model
F. Ucar, et al., Diskapi Yildirim Beyazit Training and Research Hospital, Department
of Clinical Biochemistry, Ankara, Turkey
B-08: Comparison of Lipid-Lowering Effects of 5’-Palm-(CT)6CNH2 and Atorvastatin
Z. G. Dikmen, et al., University of Hacettepe, Faculty of Medicine, Department of Medical
Biochemistry, Ankara, Turkey with AuraSense Company, Skokie, IL
B-09: New Sensitive Anti-Müllerian Hormone (AMH) ELISA’s for Non-Human Primate,
Rodent, Equine, Bovine, Canine and Other Species
A. Kumar, B. Kalra, A. S. Patel, S. Shah. Ansh Labs, Webster, TX
8
Joseph F. Dooley, PhD, DABCC, FACB
to Receive 2013 DACC Award for
Outstanding Contributions to Animal Clinical Chemistry
A highlight for Division of Animal Clinical Chemistry (DACC) attendees in
Houston this July will be the presentation of the Award for Outstanding Contributions to Animal Clinical Chemistry.
Establishing this award was a milestone
for the AACC‟s first division, and it is
now in its 21st year of recognizing significant contributions in the field of animal clinical chemistry. Siemens Healthcare Diagnostics‟ commitment
to supporting excellence in clinical laboratory medicine of all types, including
multispecies laboratories,
is underscored by their continuing sponsorship of this annual DACC award.
This year‟s recipient will be Joseph F. Dooley, PhD,
DABCC, FACB.
As in past years, the award will be presented to Dr.
Dooley at the DACC reception hosted by Siemens
Healthcare Diagnostics at the AACC Annual Meeting
in July. Dr. Joseph F. Dooley, PhD, Diplomate
American Board of Clinical Chemistry (DABCC), and
Fellow of the Academy of Clinical Biochemistry
(FACB) as the 2013 recipient of the Award for Outstanding Contributions to Animal Clinical Chemistry. Establishing this award was a milestone for
our professional society that is now in its 21st year of
recognizing significant contributions in the field of
animal clinical laboratory medicine.
nology Associates and CEO of TriMark
Publications, an international company
providing high level white papers and
monographs on diagnostics, pharmaceutical developments, instrument design and advances in scientific developments in laboratory medicine. Dr. Dooley is a Past-Chair and a founding
member of the AACC Laboratory Animal Clinical Analysis Group (LACAG).
Dr. Dooley is a Past-Chair and was a
founding member of the American Association of Clinical Chemistry Division
of Animal Clinical Chemistry (DACC).
Joseph F. Dooley obtained his PhD
(1967) from the University of Minnesota
and post-doctoral training in clinical laboratory medicine at the University of Connecticut School of Medicine. Dr. Dooley has had many honors and distinctions; including a Certificate of Recognition from the
American Association for Clinical Chemistry Division
of Animal Clinical Chemistry in 2004. He has published over fifty scientific papers on diagnostic medicine and biochemistry, three books, including “The
Coming Cancer Breakthroughs”, and over 80 monographs on molecular medicine, diagnostic testing
and life science sectors, including „Biomarker Technology Platforms for Cancer Diagnoses and Therapies,‟ „Pharmacogenomics for Clinical Use and in
Drug Development,‟ and „Companion Biomarkers in
Drug Development‟. Dr. Dooley‟s books have been
published in five languages. Dr. Dooley speaks
regularly at scientific and business conferences and
has chaired over 25 scientific sessions in diagnostics around the world.
Dr. Dooley will be honored at a DACC Award Reception on Tuesday July 30th that is sponsored by
Siemens Healthcare Diagnostics. The DACC
Awards and Executive Committees are proud to recognize Dr. Joseph F. Dooley as the 21st recipient of
this award as a scientist who will continue the legacy
of excellence that our previous recipients have represented.
Jon P. Kimball
Jon P. Kimball, Chair, Awards Committee
AACC Division of Animal Clinical Chemistry
Dr. Dooley has been notable in developing and exploiting a range of clinical biochemistry applications
to investigate pharmacologic toxicity in laboratory
animals, particularly the early assessment of SDH,
5‟-NT and AST isoenzymes as biomarkers of hepatotoxicity during his tenure at Pfizer Central Research, serving as Laboratory Director of the Clinical
Pathology Laboratory in the Drug Safety Evaluation
Division. After leaving Pfizer in 1983, Dr. Dooley became a founder and first laboratory director of
Dianon, a national cancer testing laboratory, which
was eventually acquired by LabCorp. He went on to
establish his own chain of clinical laboratories in
New England and New York. These too were eventually acquired by large national laboratories.
Dr. Dooley is presently a senior partner at BioTech-
9
Edith Williams, Patricia Carthage, and Rosemary Nicklaus Honored at
Spring Meeting for Meritorious Service, Dedication, and
Contributions to the DACC
Debra Wescott & David Pavlock Awarded Best Poster / Travel Award
Rich Giovanelli, Rosemary Nicklaus, Bob Emmons
Edie Williams, Bob Emmons, Pat Carthage, Rosemary Nicklaus
David
Pavlock
-/Debra
Wescott
Edie Williams, Jon Kimball, Pat Carthage
Patricia Carthage
Rich Giovanelli, Pat Carthage, Bob Emmons
Sponsors: Sysmex and Idexx
Edith Williams
10
In Memoriam
Kent Gossett –Former DACC Chair, Colleague, and Friend
Kent A. Gossett, DVM, PhD, ACVP, MBA had been employed 15 years in
academic and pharmaceutical industrial clinical pathology and a DACC
member for over 10 years when elected to lead the Division in 1996. Kent
was the first to fall under a bylaw change (since rescinded) that mandated
a two year term of office as chairperson. He therefore served as Chairelect in 1997, Chair in 1998 & 1999, and Past-chair in 2000 & 2001. Hallmarks of his leadership were meetings that introduced the membership to
cutting edge technology. Kent was a member of the Long Range Planning
Committee and a member of The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. He often gave presentations at DACC meetings. He placed emphasis on the non-traditional role
of clinical pathology in drug discovery and development. Kent was a Past
President of the American Society for Veterinary Clinical Pathology. He co
-authored a Clinical Laboratory News Article titled Division of Animal Clinical Chemistry: A Proud History and Bright Future.
Kent Gossett was a dedicated, forward looking leader and a respected clinical pathology expert. He
was also an intelligent, warm, and wonderful person to be around. He will be greatly missed! The
DACC sends its condolences to his wife and family.
Kent Gossett of Wallingford, PA passed away June 8, 2013 at the age of 60 after a long battle with
lung cancer; he was surrounded by his family. He is survived by his loving wife, Diane H. Gossett;
their children: Christopher M. and fiancée Amber L. Spielman of Wallingford, PA, Katherine L. and
Anna B. of New York, NY; and grandson, Christian A. He was born in Greenfield, Indiana, June 1st,
1953, the son of Marilyn Walter Gossett and the late Dr. Frank O. Gossett, DVM. Kent received his
MS and DVM from Purdue University, his PhD in Veterinary Clinical Pathology from Louisiana State
University, and received his MBA from the Wharton School of the University of Pennsylvania. He was
a Diplomat of the American College of Veterinary Pathologists. He is survived by his mother, Marilyn
W. Gossett of Greenfield, IN; his siblings Larry C. Gossett of Greenfield, IN Carol A. Thorne and
Susan K. Gossett of Indianapolis, IN and Mark W. Gossett of Mountain Lakes, NJ and their families.
Kent most recently worked as a Partner at SRone in Conshohocken, PA, the corporate venture capital
arm of GlaxoSmithKline. Over the past few years he sat on the boards of more than nine companies,
contributing to the success of those organizations as they pushed their biotechnical innovations
through clinical trials. In his final weeks, he spent many happy days with his wife, children, grandson,
and puppies watching movies and LSU games. He was thankful for the laughter they all shared together up until the very end. The family would like to extend their heartfelt thanks to Dr. Roger B.
Cohen at the Perelman Center for Advanced Medicine at UPenn, who provided extensive support as a
friend and doctor to Kent and his family during his treatment over the last 6 years, as well as to the
Wissahickon Hospice. His family will be holding private receptions in his memory in both Greenfield,
IN and Wallingford, PA.
11
Images from the 2013 Spring Symposium
Cardiac and Skeletal Muscle Injury in Drug Development:
Advances in Biomarkers Assessment and Clinical Translation
Richard Goldstein
Warren Glaab
Brante Sampey
Nelly Aranibar
Moderator: Rich Giovanelli
Carl Morris
Greg Friedrichs
Michael Dunn
Bill Reagan
12
The DACC Needs YOU!
Members Are Needed to Run for Office
and or Volunteer to Serve the
Division in the Following Capacities:
Elected Office
Candidate for Chair-Elect
Candidate for Secretary
Candidate for Nominating Committee Member
Volunteer Positions Available
Membership Committee
Scientific Program & Long Range Planning Committee
Your Participation in OUR Division is Vital
to Ensure Continued Quality of the
DACC’s Business and Educational Activities
You Should Consider Running for Chair-Elect
The position of Chair-Elect is always the most difficult to recruit candidates for to run for election.
Universally, individuals who have served in the
succeeding positions of Chair-Elect, Chair and
Past-Chair of the DACC have agreed that it has
been a great growth experience both personally
and professionally. The high degree of continuing
engagement in the DACC by those who have held
these positions provides a pool of talent to ease
the new officer into the responsibilities of the position. Most previous Chair-Elects have come into
the position without previous experience at leading
this type of organization, but with the help of others
quickly mastered the position. Being Chair-Elect
does require an extra measure of effort and time
commitment from the individual over a three year
period, but if you have benefited from the DACC
meetings, newsletter, listserv, or personal contacts
you should ask yourself:
• Is it time to give back to the organization?
• How would my scientific community be impacted
if there were no DACC?
Top ten reasons to run for Chair-Elect:
 Work with a great group of individuals committed to
the field of Animal Clinical Chemistry
 Opportunity to interact with the top leaders in the
field of Clinical Chemistry
Gain valuable contacts throughout the scientific
community
 Gain experience in setting up scientific sessions in
connection with Division & AACC Annual meetings
 Interact with colleagues from industry and academia
to further DACC goals
 Gain a greater understanding of and visibility in your
own organization as you interact with potential
speakers and management
 Gain experience running an organization that
encompasses individuals from many career paths
 Impact the scientific direction in the field of Animal
Clinical Chemistry
 Add to the long history of scientific excellence for
the DACC
 Give back to an organization that has enriched your
career
13
Volunteers are needed for
DACC committees. Join your
colleagues in determining
the future direction of
YOUR division.
AACC ANNUAL
MEETING
Houston, Tx
July 27, 2013
AMERICAN COLLEGE of
TOXICOLOGY
ANNUAL MEETING
San Antonio, TX
November 3-6, 2013
ACVP / ASVCP
ANNUAL MEETING
Montreal, QC, Canada
November 16-20, 2013
Annual Meeting Round Table
Systems Management: Improving Quality and
Productivity Through Automation and a
Customized Laboratory Information System
Session #43128
Speaker: Johanna Wisniewski -Pfizer Inc. Groton, CT
Systems management is a key component of achieving maximal laboratory productivity. This session will focus on rules
based automation, customization of LIS applications, and system monitoring tools. Aspects of autoverification, utilization of
customized reports, interfaces, batch tools, and middleware
applications will be discussed.
2013 DACC Fall Elections
This is the Year YOU Should Run for Office
The Division Depends on YOUR Volunteerism!
See Which Positions Are Open On Page 14
14
DACC NEWS
AACC’s Division of Animal Clinical Chemistry
DACC NEWS Editor Emeritus
Robert E. Emmons
585-924-5019
[email protected]
DACC NEWS Editor
Mike Bieraugel
714-246-6051
[email protected]
DACC NEWS Associate Editor
Jon P. Kimball
919-967-4016
[email protected]
DACC 2013 Executive Committee
Chair
Richard P. Giovanelli
Chair-Elect
David Desmond
Pfizer Global Res. & Dev.
860-686-2176
[email protected]
AbbVie, Inc.
847-935-6540
[email protected]
Past-Chair
Kay Criswell
Pfizer Global Res. & Dev.
860-686-9430
[email protected]
Treasurer
Secretary
David F. Adams
Lila Ramaiah
732-371-2550
ext 2683
[email protected]
GlaxoSmithKline R&D
610-270-7228
[email protected]
DACC 2013 Committees
Nominating (Year as Chair)
Membership
Fund Raising
Awards
Doug Thudium (2013)
Karen Lynch (2014)
Dirk Sprenger (2015)
Tammy Lambert (2016)
Kay Criswell (Exec Rep)
Volunteers Needed!
Jon Kimball
Doug Neptun
Chris Perigard
Lila Ramaiah (Exec Rep)
Jon Kimball (Chair)
Kay Criswell
Bob Emmons
Doug Neptun
Scientific Program & Long Range Planning
Richard Giovanelli1,3
Kay Criswell2
David Desmond4
Doug Thudium
Jon Kimball
Volunteers Needed!
Principal Organizer: 1: 2013 Spring Symposium, 2: 2013 Annual Meeting Symposium,
3: 2014 Annual Meeting Symposium, 4: 2013 Annual Meeting Lunch & Learn
15